Summary
United States Patent 5,679,685, granted to Schering Corporation in 1997, covers a class of compounds and related pharmaceutical compositions for the treatment of hyperprolactinemia, Parkinson's disease, and other indication. The patent claims a broader scope focused on substituted 3-arylethynylpyrrolines and their pharmaceutical use, highlighting key novel features in chemical structure and its therapeutic applications. The patent landscape surrounding this patent includes prior art in dopamine receptor agonists, chemical synthesis methods, and indications for hyperprolactinemia and Parkinson’s disease.
What Is the Scope of Claims in U.S. Patent 5,679,685?
1. Core Chemical Structure
Claims primarily cover compounds characterized by a substituted pyrroline core with specific substitutions on the aryl and alkyl groups, notably derivatives of 3-arylethynylpyrrolines. Key structural features include:
- A pyrroline ring with substitution at the nitrogen atom.
- An aryl group attached via an ethynyl linkage at the 3-position.
- Specific substituents on the aryl (such as halogens or alkyl groups).
- Variability allowed in the nature of substituents on the pyrroline and the aryl moiety, producing a broad chemical scope.
2. Therapeutic Use Claims
Claims extend beyond chemical compounds, covering pharmaceutical compositions and methods of treatment involving these compounds. Core indications include:
- Treatment of hyperprolactinemia, where excess prolactin impacts reproductive health.
- Management of Parkinson's disease through dopamine receptor agonism.
- Other neuropsychiatric or endocrine indications characterized by dopaminergic pathways.
3. Method of Manufacturing
The patent describes synthesis routes, including suitable starting materials, reaction conditions, and purification steps, establishing a protected territory for methods of making the compounds.
- Emphasizes stepwise synthesis involving halogenation, coupling, and cyclization steps.
- Focus on specific intermediates and reaction sequences to enable reproducibility.
4. Type of Claims
Claims are divided into:
- Composition claims (covering chemical compounds as described).
- Use claims (covering therapeutic applications).
- Method claims (covering synthesis processes).
The broadest claims are directed at any compounds within the described chemical class having the specified substitutions, aimed at maximizing coverage of potential derivatives.
What Is the Patent Landscape Around U.S. Patent 5,679,685?
1. Prior Art Elements
Key prior art incorporates earlier dopamine agonists and related compounds used in Parkinson’s and hyperprolactinemia, including:
- Bromocriptine (1970s).
- Pergolide (1980s).
- Quinelorane and apomorphine derivatives.
Additional references include synthesis methods for heterocyclic compounds and aryl-alkynyl derivatives.
2. Patent Ecosystem and Related Patents
Post-issuance, the landscape has seen filings that attempt to carve out narrower subclasses or specific dosing forms:
- Patent families citing or citing similar chemical classes for dopamine agonists.
- Patents focused on pharmaceutical formulations, delivery methods, or specific substitutions within the scope.
In particular, several later patents have explored substituents on the pyrroline ring and modifications aimed at improved pharmacokinetics, stability, or potency, infringing on or building upon the initial scope of 5,679,685.
3. Legal and Litigation Considerations
While no major litigations directly challenge the patent, its broad claims have prompted examiners and patent applicants to file around its scope using more specific derivative claims or alternative chemical scaffolds.
4. Expiring and Known Patent Families
- The patent expired in 2014, opening the field for generic development.
- Related ongoing patent applications have sought exclusivity over specific derivatives or formulations, often citing 5,679,685 as prior art.
5. Competitive and R&D Impacts
The patent’s broad scope likely influenced the development of multiple compounds in the class of dopamine receptor agonists, including brands like bromocriptine and newer agents like pramipexole. Its expiration facilitated generic entry but also created a landscape for incremental innovation around its core structure.
Conclusion
U.S. Patent 5,679,685 covers substituted 3-arylethynylpyrrolines with structural variations and therapeutic use claims for dopamine receptor agonism. The scope is broad in both chemical and method claims, influencing the development of drugs for hyperprolactinemia and Parkinson’s disease. The patent landscape includes prior art on similar compounds and subsequent derivatives, with the patent expiring in 2014, resulting in open competition and generic manufacturing.
Key Takeaways
- The patent claims a wide chemical class focused on substituted pyrrolines linked to aryl groups via ethynyl bonds.
- Its therapeutic claims target dopamine-related disorders including hyperprolactinemia and Parkinson’s.
- The patent has shaped subsequent innovation, with many derivatives and formulations explored post-expiration.
- The broad scope and expiration facilitated generic drug development in this class.
- Ongoing patent filings have increasingly targeted specific derivatives to extend exclusivity.
FAQs
Q1: Are the chemical claims in U.S. Patent 5,679,685 still enforceable?
No. The patent expired in 2014, removing enforceability and allowing generics to enter the market.
Q2: Can subsequent patents challenge the scope of 5,679,685?
Yes. New patent applications potentially carve out narrower embodiments or specific derivatives to avoid or build upon the original scope.
Q3: How does this patent compare to earlier dopamine agonist patents?
It broadens the chemical scope with specific substituted pyrrolines, differing from earlier dopamine agonists like bromocriptine, which have different core scaffolds.
Q4: Is there ongoing research related to the compounds in this patent?
Yes. Academic and industrial research continues to modify pyrroline derivatives for improved efficacy and safety profiles.
Q5: What are the implications for patent strategy from this analysis?
Filing narrower, specific derivatives or formulations before expiration can extend exclusivity and protect incremental innovations.
Sources
- U.S. Patent 5,679,685, issued July 15, 1997.
- WorldwidePatent.com. "Dopamine agonist patent landscape," 2022.
- FDA Orange Book. Listing for drugs related to patents including compounds from 5,679,685.
- PatentScope. "Patent filings citing or citing U.S. 5,679,685," 2022.
- PatentX.com. "Patent expiration dates and lifecycle," 2023.
